Clinical Trial Update: A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines [Phase 3]

View source ↗

Summary

Phase 3 non-inferiority trial comparing AbobotulinumtoxinA from Espad Pharmed with Dysport for correction of moderate to severe glabellar lines has been complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Frown Lines
• Glabellar Lines

Drugs mentioned

• AbobotulinumtoxinA (Espad Pharmed) (abobotulinumtoxinA)
• Dysport (abobotulinumtoxinA)

Snippet

Sponsor: Espad Pharmed | Conditions: Glabellar Lines, Glabellar Frown Lines | Phase 3 | Status: COMPLETED